FDA approves first rapid-acting insulin biosimilar for patients with diabetes
Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with ...
Endocrinology Advisor1d
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.
PharmiWeb3d
Insulin Delivery Devices Market Size & Share | Growth Analysis 2035
The global Insulin Delivery Devices Market was valued at USD 30.9 billion in 2022 and is expected to grow significantly, ...